Erasca

ERASCA INC

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc

News

Health Care

Press Releases

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

General

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Earnings

Erasca Reports First Quarter 2025 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences in June

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

Small Cap

Opinion

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

ARAY

CLRB

ERAS

INTS

ONCY

TSX:ONC

Absci

Akebia Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Geron

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gyre Therapeutics

I-MAB

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Myriad Genetics

Nurix Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Regenxbio

Savara

Tyra Biosciences

UroGen Pharma

Verastem

Stifel

B of A Securities

Morgan Stanley

HC Wainwright & Co.

Raymond James

Comments

Erasca

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL